Sam Brusco, Associate Editor09.08.22
Medtronic has earned U.S. Food and Drug Administration (FDA) 510(k) clearance for its RespArray patient monitor for procedural sedation and medical-surgical units.
RespArray includes the company’s Nellcor pulse oximetry and Microstream capnography, as well as electrocardiogram (ECG), non-invasive blood pressure (NiBP), and temperature monitoring.
Medtronic plans to initiate limited market release in late Q4 2022, followed by full release in early 2023.
The patient monitor was designed with smart algorithms to help spot respiratory compromise early and lower alarm fatigue. It also features simple connectivity and integrates into a hospital’s EMR to boost workflow. This means less time manually charting and more time to focus on patients.
“Helping to keep patients safe is our top priority,” Frank Chan, president of Medtronic’s Patient Monitoring business told the press. “We engineered RespArray to expand access in procedural sedation and medical-surgical units to critical monitoring technologies that are always watching out for patients. These technologies can help clinicians detect respiratory compromise early so they can intervene fast.”
RespArray includes the company’s Nellcor pulse oximetry and Microstream capnography, as well as electrocardiogram (ECG), non-invasive blood pressure (NiBP), and temperature monitoring.
Medtronic plans to initiate limited market release in late Q4 2022, followed by full release in early 2023.
The patient monitor was designed with smart algorithms to help spot respiratory compromise early and lower alarm fatigue. It also features simple connectivity and integrates into a hospital’s EMR to boost workflow. This means less time manually charting and more time to focus on patients.
“Helping to keep patients safe is our top priority,” Frank Chan, president of Medtronic’s Patient Monitoring business told the press. “We engineered RespArray to expand access in procedural sedation and medical-surgical units to critical monitoring technologies that are always watching out for patients. These technologies can help clinicians detect respiratory compromise early so they can intervene fast.”